Tag:
United Kingdom
Latest Headlines
Latest Headlines
U.K. report says NICE drags its feet on drug approvals
British media are reporting on a study suggesting that U.K. patients twiddle their thumbs for up to 9 years as the National Institute for Health and Clinical Excellence deliberates over new products.
Patheon exiting most manufacturing at U.K. plant
The company also plans to move to other facilities most of its product development work at Swindon that requires commercialization.
Novartis may weigh Lucentis price cut in U.K.
Last week, data comparing that product to its close cousin, Avastin, in macular degeneration patients found the two meds roughly equivalent, efficacy-wise. This week, a U.K study concluded that the two offered similar results with a similar safety profile.
U.K. officials ready $286M fund to fuel a biotech revival
U.K. officials are preparing for the imminent launch of a $286 million fund designed to revive the country's biotech industry.
GSK's Witty winning at pharma chess in post-blockbuster era
Andrew Witty has made a number of deft moves in recent years to position GlaxoSmithKline ($GSK) for growth despite numerous challenges to Big Pharma.
GSK to build new U.K. site, create up to 1,000 jobs
GSK said it will build a new facility in Ulverston, Cumbria, to boost production of ingredients for its meds and vaccines.
GSK to invest more than £500 million in new manufacturing in U.K.
GlaxoSmithKline ( $GSK ) has decided to build a £350 million ($463 million) plant in Ulverston, U.K., but to also invest another £230 million ($304 million) at the other three sites the company was considering.
UPDATED: GSK investing in U.K. vaccine manufacturing
GlaxoSmithKline has announced that it intends to invest more than £500 million ($794 million) and create up to 1,000 jobs in vaccine and pharmaceutical manufacturing in the U.K.
Sanofi cuts continue with closing of manufacturing plant in U.K.
Sanofi ( $SNY ), which has spent the last year trimming manufacturing and R&D operations around the globe, has taken aim at another U.K. facility.
Pfizer's new U.K. cold storage facility has hot new vaccines line
Pfizer ( $PFE ) has thawed relations with the U.K. by opening £7 million ($10.9 million) worth of cold storage improvements at its packaging and distribution facility in Havant, near Portsmouth.
